This story was originally published on The Limbic  Improving the outcomes of multiple myeloma patients with high-risk abnormalities (HRA) continues to pose a therapeutic challenge, but the future of multiple myeloma treatment is bright, with so many active drugs and immunotherapies on the horizon, a recent Amgen-sponsored educational meeting in Perth heard. Doctor M Hasib...Continue Reading